Scientific Officer BioAgilytix Labs Durham, North Carolina
Description: Anti-sense oligonucleotides (ASOs) are a promising novel therapeutic modality in the field of genetic diseases. Anti-drug antibody (ADA) assessment is a critical part of clinical studies that measure the safety and efficacy of these therapeutics. This presentation will detail the challenges involved in measuring anti-drug antibody (ADA) responses to ASOs, and the strategies that can be used to make sure the ADA assays meet regulatory expectations.
Learning Objectives:
Participants will learn about ASOs and how they are being used to treat genetic diseases.
Participants will gain an understanding of how to design anti-drug antibody assays to measure immune responses to ASOs.
Upon completion, participants will be able to understand the challenges, and potential solutions involved in ADA assay validation for ASOs and important considerations in sample analysis.
